a2 National Symposium

Mahesh Narayanan, MS, is the managing partner of Neuvation Ventures, an impact investment fund responsible for identifying and investing in early-stage companies, research, and ideas in the brain health sector. He is also the co-founder of MatchPlay, a venture capital firm that brings together strategic advisory, investment, and operational expertise to help organizations accelerate growth. With deep experience in entrepreneurship, venture building, and leadership, he works closely with founders and teams to translate ideas into sustainable, high-impact ventures.

Narayanan is an experienced investor and accelerator director with over 15 years in biotechnology and a founder of multiple companies in life sciences and technology with two successful exits. He has mentored 100+ startup companies, with focus in brain health and other deep tech innovations.

Hon Pak, MD, MBA, is a seasoned corporate physician executive with more than 25 years of healthcare strategic leadership in health information technology across both the public and private sectors. Dr. Pak is a change agent and has a proven track record in steering sustainable, profitable rapid growth and value creation in small and large organizations through his vision and team-based leadership. He is a problem solver and has also led several innovative healthcare companies/organizations through many operational and strategic transformations. He has also served as president and on the board of directors for several public and private organizations and is internationally recognized for his expertise in telemedicine, healthcare, and healthcare IT. Over the last 12 years, Dr. Pak has performed in numerous senior leadership roles providing strategic business development and capture support in both the commercial and federal healthcare sectors.

‍

Kunal Parikh, PhD, is an assistant professor at the Johns Hopkins University (JHU) School of Medicine in the divisions of glaucoma and nanomedicine at the Wilmer Eye Institute and at the Center for Bioengineering Innovation and Design within the JHU Department of Biomedical Engineering. Dr. Parikh leads a translational, R01-funded, interdisciplinary lab of engineers, scientists, and clinicians working together to create and translate novel biomedical solutions to alleviate human suffering at scale. His research program utilizes biodesign and insight-informed innovation methodologies to develop digital health technologies, surgical instruments, medical devices, multi-functional biomaterials, and therapeutics that can be readily scaled and adopted into clinical practice to enable access to care, improve treatment outcomes, and prevent post-operative complications. Several of his laboratory’s inventions have been licensed to industry or formed the basis for startup companies (Eyedea Medical, Cove Therapeutics, Samata Therapeutics, Visilant), including multiple commercial products.

Previously, Dr. Parikh built and served as the executive director of the Social Innovation Lab at JHU, where he advised and funded mission-driven entrepreneurs. Prior to arriving in Baltimore, he was the founding CEO of Core Quantum Technologies, a venture-backed biotechnology company developing superior imaging and detection reagents. Dr. Parikh earned his PhD in biomedical engineering at JHU where he was a Roche/ARCS Scholar and National Science Foundation Graduate Research Fellow.

Phillip Phan, PhD, is the Alonzo and Virginia Decker Professor of Strategy and Entrepreneurship at Johns Hopkins Carey Business School, a professor in the Division of Geriatric Medicine and Gerontology at Johns Hopkins Medicine, and a core faculty member at the Armstrong Institute for Patient Safety and Quality. At JH AITC, Dr. Phan serves as co-principal investigator and Networking and Mentoring Core director. An author of more than 300 peer-reviewed research articles and author/editor of 13 scholarly books, Dr. Phan’s academic and professional work focuses on the commercialization of biomedical technology and health services research, technological innovations that emphasize patient safety, quality, and biomedicine, as well as AI applications for patient care. Additionally, he is the co-founder of P4Microbiome Inc., an antimicrobial peptide-based biotech startup; Pistevo LLC, a developer of AI solutions to improve medical billing accuracy; and FKP Consulting LLC, a consultancy devoted to vascular and interventional radiology.

Rosalind Picard, ScD, is Grover M. Hermann Professor in Health Sciences and Technology at the MIT Media Lab, where she is founder and director of the Affective Computing Research Group, associate academic head, and associated with the MIT Center for Neurobiological Engineering. She is author of the book Affective Computing and co-author of hundreds of peer-reviewed scientific and engineering articles in AI, wearable digital health technologies, affective computing, and human–computer interaction (h-index > 120). She is co-founder and chief scientist of Empatica, providing FDA-cleared digital biomarkers and medical quality data for clinical trials and research studies, and providing medical smartwatches that monitor for tremors and gait changes in Parkinson’s disease and for seizures in epilepsy. Dr. Picard is also co-founder of Affectiva, providing emotion AI technology, now a part of Smart Eye AB. An inventor on over 100 worldwide and U.S. patents, she is a popular speaker with a TED Talk of over 2 million views.

Dr. Picard is a member of the National Academy of Engineering and the National Academy of Inventors, and a fellow of the Institute of Electrical and Electronics Engineers (IEEE), Association for Computing Machinery (ACM), and Association for the Advancement of Affective Computing (AAAC). She has been honored with the 2022 International Lombardy Prize for Computer Science Research, described as the “Nobel” in Italy, the 2025 Trotter Prize in Information, Complexity and Inference, and the 2026 IEEE Medal for Innovations in Healthcare Technology.

‍

Kyle Rand is the co-founder and CEO of Rendever, an AgeTech company leveraging immersive technology to improve the lives of older adults. Under his leadership, Rendever has pioneered the use of virtual reality to reduce social isolation and support cognitive and emotional well-being across senior living communities and healthcare settings. As a pilot awardee with the MassAITC program, his research explores the ability to use RendeverFit®, a virtual reality fitness platform, to create a digital biomarker to remotely assess changes in physical and cognitive functions in order adults receiving physical therapy while aging in place. He is also PI on an STTR grant, in collaboration with RAND, that brings home health dementia caregivers into the design process of a virtual reality platform seeking to mitigate their work-related burden and social isolation by cultivating a virtual community of support.

Rand graduated with dual degrees in biomedical engineering and neuroscience from Duke University, and was a Pratt Research Fellow at the world-renowned Nicolelis Lab. Since joining the tech world, he has led the development of a niche research-based social network, created a crowdfunding platform for ecological conservation, and architected a grassroots initiative focused on increasing healthcare access in populations-in-need. He was named to Forbes 30 Under 30 in 2019 and Rendever was honored on the 2022 TIME list of 100 Most Influential Companies.

Rick Robinson has led teams building products and boosting startups at AARP’s Innovation Labs and the AgeTech Collaborative for 6 years. Prior to that he cofounded venture-backed and public companies, with two exits, and led product and content functions at AOL, Sprint, Politico, and National Geographic.

‍

Orit Rozenblatt-Rosen, PhD, is head of the Cell and Tissue Genomics Department and co-leads foundational data for foundation models at Genentech. She also co-leads the Standards and Technology Working Group for the Human Cell Atlas. Dr. Rozenblatt-Rosen is a pioneer of single-cell genomics, especially in the context of human tissues. She is a strategic leader with extensive experience driving drug discovery and innovation at the intersection of genomics, biology, and AI. She is an expert in leveraging the “lab-in-the-loop” approach to identify novel targets, compounds, and biomarkers and is recognized for accelerating disease biology insights in oncology, neuroscience, and immunology through robust cross-functional collaboration.

Prior to joining Genentech, Dr. Rozenblatt-Rosen held scientific appointments in academia over a 20-year period, first at the Dana-Farber Cancer Institute and then at the Broad Institute of MIT and Harvard. She received her BSc and MSc degrees from Tel Aviv University, and PhD from the Weizmann Institute of Science. She conducted postdoctoral studies at the Weizmann Institute of Science and the Dana-Farber Cancer Institute.

Anindita (Annie) Saha is associate director for strategic initiatives for the Digital Health Center of Excellence (DHCoE) in the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration (FDA) where she supports promoting innovation of digital health technologies, including those enabled by AI. She is also serving as the acting associate director for data science and AI policy at the FDA Center for Drug Evaluation and Research (CDER) to support the use of AI across the drug development lifecycle. Additionally, Saha helped incubate and continues to support to advance the science and adoption of patient input as evidence, including patient preference information (PPI) and clinical outcome assessments (COAs).

Previously, Saha was the director of the Partnerships team in CDRH where she oversaw a broad program portfolio, supporting several strategic partnership and regulatory science programs. Saha started at FDA as a researcher in the Office of Science and Engineering Laboratories in imaging display technologies. She has a BS in bioengineering and minor in history from the University of Pittsburgh.

Raghav Sehgal, PhD, is an associate research scientist in computational biology at Yale University and a scientific principal at Longevity Tech Fund, a venture capital firm that focuses on investing in companies that are innovating in the fields of AI, digital health, medical devices, and diagnostics. Dr. Sehgal is passionate about solving the mysteries of aging and extending healthy lifespans. He is developing machine learning and deep learning tools to analyze multi-omic and multi-modal data, and to answer questions about what biological systems drive aging, how we can measure them, and if we can reverse them. As part of his research, he built SYMPHONYAge a patented biomarker that can measure aging in 11 different organs from a single blood draw.

At Longevity Tech Fund, Dr. Sehgal provides expert advice on potential investment opportunities and helped raise their second fund by building strategies for future investments. He has 10 years of experience in applying data science and AI to the biomedical space as a scientist, engineer, product manager, team builder, academician, and entrepreneur. He completed his PhD at Yale University, is a Forbes 30 Under 30 honoree, and has received awards such as the Gruber Science Fellowship and Impetus Aging Grant.

‍

Arman Sharma serves as Deputy Chief AI Officer for the U.S. Department of Health and Human Services, where he leads implementation of the HHS AI Strategy. He has a background in genomics, health system technology implementation, process and quality improvement, and health economics.

Russell H. Taylor, PhD, is a John C. Malone Professor in the Department of Computer Science at Johns Hopkins University (JHU) with secondary appointments in the Department of Mechanical Engineering and the School of Medicine’s Departments of Otolaryngology–Head and Neck Surgery, Radiology and Radiological Science, and Surgery. He has more than 50 years of professional experience in the fields of computer science, robotics, and computer-integrated interventional medicine. For more than a decade, he served as the director for JHU’s Laboratory for Computational Sensing and Robotics, one of the most technologically advanced robotics research centers worldwide and an international leader in the areas of medical robotics, autonomous systems, and bio-inspiration.

Dr. Taylor is also a member of JHU’s Malone Center for Engineering in Healthcare, Institute for Assured Autonomy, and Data Science and AI Institute. He is a member of the National Academy of Engineering and a fellow of the Institute of Electrical and Electronics Engineers (IEEE), the National Academy of Inventors, the American Institute for Medical and Biological Engineering (AIMBE), the Medical Image Computing and Computer Assisted Intervention (MICCAI) Society, and the Engineering School at the University of Tokyo. Prior to his appointment at JHU, he completed his PhD in computer science at Stanford University and subsequently served at IBM Research for nearly two decades, where he developed the AML robot programming language and held management roles in robot systems and technology, automation technology, and computer-assisted surgery.

‍